EN PL
The consensus on rituximab administration in the treatment of patients with rheumatoid arthritis
 
More details
Hide details
 
Online publication date: 2007-07-02
 
 
Reumatologia 2007;45(3):115-119
 
KEYWORDS
ABSTRACT
Rituximab is a biologic B-cell targeted treatment in rheumatoid arthritis. A present consensus statement was formulated in order to determine indications and contraindications of using rituximab in rheumatoid arthritis. This statement was established based on data from randomized controlled trials on haematology and rheumatology. Rituximab in combination with methotrexate constitutes a major advance in the treatment of adult patients with rheumatoid arthritis who have had inadequate response or intolerance of disease modifying anti-rheumatic drugs (DMARDs) including one or more TNF-blocking agents.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top